Executive leadership transition On January 16, 2026, Emmecell, a clinical-stage biotechnology company pioneering magnetic cell delivery (MCD) technology, officially appointed Ramin Valian as Chief Executive Officer (CEO). In this role, Mr. Valian will oversee corporate strategy, clinical and regulatory development, strategic partnerships, and operational growth as the company approaches pivotal clinical milestones.
Professional background of the new CEO Ramin Valian is a veteran biopharmaceutical executive with over 20 years of global commercial and strategic leadership experience in the eye care sector.
-
Previous Experience: Prior to joining Emmecell, he held senior leadership positions at Allergan and AbbVie, where he successfully led the global launches of six high-impact ophthalmic products.
-
Expertise: His domain expertise spans corneal diseases, surgical and interventional glaucoma, retina, and consumer eye care.
Strategic vision and objectives This appointment coincides with Emmecell’s preparation for pivotal clinical trials in corneal disease. Emmecell’s platform utilizes magnetic nanoparticles to precisely and non-invasively position therapeutic cells within the eye, representing a paradigm shift in regenerative medicine. The company’s primary objective is to develop non-surgical alternatives to traditional corneal transplants while expanding the platform’s application to retinal conditions, such as geographic atrophy.
Source: https://www.contractpharma.com/breaking-news/emmecell-appoints-ramin-valian-as-ceo/